Clinical trials: acne
Acne Vulgaris
Efficacy and Safety Study of 2 Different Concentrations of CD1579 Gels Versus Vehicle in the Treatment of Acne Vulgaris.
This study is to assess the efficacy and safety of two concentrations of CD1579 (2.5% and 5%) versus vehicle in the treatment of acne vulgaris in the Japanese patients.
- Trial name
- NCT02073461
- Testing
- CD1579 2.5%, CD1579 5%, Vehicle
- Where
- 6 sites in Japan
- Volunteers
- 236 people
- Sponsor
- Galderma R&D
Acne
Efficacy of Cosmetic Product RV3278B-OS0386 on Skin Surface Ecosystem, in Teenagers with Mild to Moderate Facial Acne
The aim of this exploratory study is to better understand the mechanisms of action of the RV3278B-OS0386 cosmetic product on the cutaneous ecosystem, in acne context.
- Trial name
- NCT06659861
- Testing
- RV3278B-OS0386, RV4632A-RY1845
- Where
- Romania
- Volunteers
- 52 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Acne Vulgaris
Risk Minimisation Study for Diane-35 and Its Generics
The study will be an observational, cross-sectional study of knowledge, understanding, and self-reported behavior among a sample of physicians with recent experience in prescribing Diane-35 or its generics in a total of five…
- Trial name
- NCT02410031
- Testing
- Cyproterone acetate 2mg/ethinylestradiol 35 μg (Diane-35)
- Where
- 5 sites in Austria, Czechia and 3 more
- Volunteers
- 759 people
- Sponsor
- Bayer
Acne Vulgaris
1% Clascoterone Cream for the Treatment Acne Vulgaris
This is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of 1% Clascoterone Cream in the treatment of acne vulgaris.
- Trial name
- NCT07457294
- Testing
- 1% Clascoterone Cream
- Volunteers
- 692 people
- Sponsor
- Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.
Acne Vulgaris
Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris
Bioequivalence with Clinical Endpoints.
- Trial name
- NCT02709902
- Testing
- Adapalene/BP gel, 0.3%/2.5%, EPIDUO® FORTE
- Volunteers
- 460 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne Vulgaris
A Study Evaluating the Efficacy and Safety of Clascoterone Cream 1% in Skin of Color Patients With Acne
Acne vulgaris is the most common skin disease in patients with skin of color and second most common in Caucasian population. The global prevalence is thought to be as high as 60-80% in individuals 12-25 years of age.
- Trial name
- NCT06415305
- Testing
- Winlevi (clascoterone) 1% cream
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Acne Vulgaris
W0265-103: A Single-Center, Evaluator-Blinded, Randomized, Placebo Controlled, Phase 1 Clinical Trial Evaluating The Phototoxic Potential Of Topically Applied Clindamycin 1.0% - Tretinoin 0.025% Gel (Ct Gel) In Healthy Volunteers
Clindamycin 1.0% - tretinoin 0.025% gel (CT Gel) is a reformulation of VELAC Gel that contains the same active ingredients (clindamycin 1.0% and tretinoin 0.025%) in a modified vehicle.
- Trial name
- NCT01929278
- Testing
- CT Gel (clindamycin 1% and tretinoin 0.025%), Vehicle gel patch, Blank patch
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Stiefel, a GSK Company
Acne
Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris
This is an open-label, multi-center study to be conducted in the United States. The study will examine the change in lesion count in subjects using Epiduo® Gel Pump (once daily) in conjunction with Cetaphil® DermaControl™ Foam…
- Trial name
- NCT01951417
- Testing
- Adapalene/BPO Gel, Moisturizer SPF 30, Foam Wash
- Where
- 5 sites in United States
- Volunteers
- 81 people
- Sponsor
- Galderma R&D
Acne Vulgaris
Study to Evaluate the Safety and Efficacy of ASC40 in Subjects With Moderate to Severe Acne Vulgaris
This is a phase2, randomized, double-blind, multi-center, multi-dose and placebo parallel controlled design. The subjects in the study group were given double-blind drugs, and they were taken (orally) after dinner every day…
- Trial name
- NCT05104125
- Testing
- ASC40 25mg, ASC40 50mg, ASC40 75mg
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
Atrophic Acne Scars
A Pilot Study to Evaluate the Safety and Effectiveness of Microneedling and Bellafill to Treat Facial Acne Scars
This is an open-label, randomized, multicenter, prospective trial assessing the efficacy and safety of microneedling treatment alone vs.
- Trial name
- NCT02643628
- Testing
- Microneedling, Microneedling followed by Bellafill treatment
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Suneva Medical, Inc.
Acne Vulgaris
Efficacy and Safety Study of VB-1953 Topical Gel for Inflammatory Facial Acne Vulgaris
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Dose-ranging Study in the Treatment of Acne Vulgaris,
- Trial name
- NCT03900676
- Testing
- VB-1953 - 2%, VB-1953 - 0% (Vehicle)
- Where
- 12 sites in United States
- Volunteers
- 480 people
- Sponsor
- Vyome Therapeutics Inc.
MILD TO SEVERE ACNE VULGARIS
Bioequivalence Study Comparing Clindamycin Phosphate (1.2%) and Tretinoin (0.025%) Topical Gel to Ziana and Placebo
ZIANA® (clindamycin phosphate 1.2% and tretinoin 0.025%) gel, marketed by Medicis, The Dermatology Company®, is a safe and effective topical therapy used for the treatment of acne vulgaris.
- Trial name
- NCT01257906
- Testing
- CLIND PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GEL, ZIANA®, Vehicle Control
- Where
- India
- Volunteers
- 1,225 people
- Sponsor
- Actavis Mid-Atlantic LLC
Acne Vulgaris
Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne
This is a multicenter open-label, prospective study in subjects with dark skin from one of the 3 ethnic/race backgrounds: Asian, Latin American and Black/African-American and with moderate to severe acne vulgaris on the face.
- Trial name
- EDeN (NCT02932267)
- Testing
- Adapalene 0.3% / BPO 2.5% gel
- Where
- 3 sites in United States, Mauritius and 1 more
- Volunteers
- 50 people
- Sponsor
- Galderma R&D
Acne Vulgaris
A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products
This study is to see if there's any difference in the amount of facial irritation when two acne products are used together on one side of the face, compared to one acne treatment product used alone on the other side of the face.
- Trial name
- NCT01313728
- Testing
- Dapsone plus Tretinoin Gel, Tretinoin Gel
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Acne Vulgaris
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
CB-03-01 is being developed for the topical treatment of acne vulgaris, an androgen-dependent skin disorder. The purpose of this study is to compare the safety and efficacy of multiple concentrations of CB-03-01 to vehicle in the…
- Trial name
- NCT01631474
- Testing
- CB-03-01, Vehicle
- Where
- 13 sites in United States
- Volunteers
- 363 people
- Sponsor
- Intrepid Therapeutics, Inc.
Acne Vulgaris
A Phase 2, 3 Arm Study of NVN1000 Gel and Vehicle Gel in Subjects With Acne
This is a 12 week clinical trial in subjects with acne vulgaris. Subjects will be randomized to NVN1000 1% Gel, NVN1000 4% Gel or Vehicle Gel twice daily.
- Trial name
- NCT01844752
- Testing
- NVN1000 1% Gel, NVN1000 4% Gel, Vehicle Gel
- Where
- 3 sites in Dominican Republic, Honduras and 1 more
- Volunteers
- 153 people
- Sponsor
- Novan, Inc.
Acne Vulgaris
A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne
Multi-center, single-blind, randomized, comparative, split-face study. The duration of the study is 8 weeks. Commencing at baseline, subjects will apply once daily both clindamycin and benzoyl peroxide gel and benzoyl…
- Trial name
- NCT00964223
- Testing
- Clindamycin and benzoyl peroxide gel (Duac® Topical Gel), benzoyl peroxide and adapalene gel (EPIDUO™ Gel)
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Stiefel, a GSK Company
Mild to Moderate Acne
Evaluation of a Photopneumatic System for the Treatment of Acne
The purpose of the study is to evaluate the safety and efficacy of a photopneumatic therapy for the treatment of acne and concomitant symptoms associated with the disease, including erythema.
- Trial name
- NCT01257555
- Testing
- Photopneumatic therapy
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Solta Medical
Acne Vulgaris
A Study of S6G5T3 in the Treatment of Acne Vulgaris
To assess the efficacy of S6G5T-3 compared to its vehicle when applied once daily for 12 weeks in participants with acne vulgaris.
- Trial name
- NCT03761810
- Testing
- S6G5T-3, S6G5T-8
- Where
- United States
- Volunteers
- 434 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Acne Vulgaris
Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris
A 12-week evaluation of the safety and efficacy of dapsone gel 5% when used with tazarotene cream 0.1% compared with tazarotene cream 0.1% monotherapy in treating moderate to severe facial acne vulgaris
- Trial name
- NCT00834210
- Testing
- Dapsone, Tazarotene
- Where
- United States
- Volunteers
- 171 people
- Sponsor
- Allergan